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Data obtained from cardiopulmonary exercise testing offers additional interpretive power over 
conventional exercise tolerance testing. When used correctly, it allows improved clinical decision-
making in patients with cardiometabolic and respiratory disease. 
 
Introduction 
The following article is the conclusion to our recently published ‘...Clinician’s Guide to 
Cardiopulmonary Exercise Testing: Part 1 – An Introduction’ (Taylor et al., 2015) 
summarising the preparatory requirements for cardiopulmonary exercise testing (CPET). 
This article will focus on the interpretation of a CPET and how to accurately apply findings 
for the purposes of patient diagnosis and risk stratification. Readers are reminded that CPET 
should be treated as any other medical investigation and every care should be taken to 
ensure rigorous calibration and test preparation. Failure to do so will compromise data 
accuracy resulting in reduced test sensitivity and specificity.   
 
Interpretation of CPET data  
Peak oxygen uptake   
Peak oxygen uptake ( O2peak) reflects the body’s maximal capacity to generate energy 
through aerobic metabolism. It can be defined using the Fick equation: 
O2 = Q x (a-vO2 diff) 
Where Q is cardiac output and a-vO2 diff is the difference between arterial and venous 
oxygen content. O2 is normally reported in absolute terms (L∙min-1) or relativised to body 
mass (ml∙kg-1∙min-1), and plotted as a function of time or workload (plot 1 of the 9-panel 
plot). Peak oxygen uptake is an independent predictor of mortality and has wide clinical 
application. The seminal paper by Mancini and colleagues (1991) was amongst the first to 
identify a threshold based on  O2 peak data (<14ml∙kg-1∙min-1) which could be used to guide 
clinical decision making for cardiac transplantation in patients with left ventricular systolic 
dysfunction. Indeed, O2peak is an integral component of the Heart Failure Survival Score 
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[HFSS] (Aaronson et al., 1997) and is listed in the current UK guidelines (Box 1) as criteria for 
referral and assessment of adults for cardiac transplantation (Banner et al., 2011).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Furthermore, Weber and colleagues (1982) developed a classification system for grading the 
severity of chronic heart failure (CHF), suggesting <10 ml∙kg-1∙min-1and >18 ml∙kg-1∙min-1 to 
be indicative of high and low risk groups.  
Integrated into most contemporary metabolic carts are decision tree algorithms designed to 
assist with diagnosing the cause of any exercise limitation (Wasserman et al., 2011). The 
first decision is to determine whether O2peak is abnormally low (<75% of predicted O2max) 
as defined by Wasserman and colleagues (2011). However, a low O2peak may be due to 
poor patient effort, therefore criteria for evaluating maximal effort should always be 
Box 1: Conventional Criteria for Heart Transplantation  
• Impaired LV systolic function 
• NYHA III (e.g. patient cannot climb one flight of stairs without symptoms) or IV 
symptoms 
• Receiving optimal medical treatment (including target or maximum tolerated 
doses of β-adrenergic antagonists, ACE inhibitors and aldosterone antagonists) 
• CRT, ICD or CRTD device implanted (if indicated)  
• Evidence of a poor prognosis, for example, 
i. Cardiorespiratory exercise testing (VO2max <12 ml/kg/min if on β-
blockade, <14ml/kg/min if not on β-blockade, ensuring respiratory 
quotient > 1.05)  
ii. Markedly elevated BNP (or NT-proBNP) serum levels despite full medical 
treatment  
iii. Established composite prognostic scoring system, such as the HFSS or 
SHFM 
BNP, B-type natriuretic peptide; CRT, cardiac resynchronisation treatment; CRTD, CRT 
and ICD treatment; VO2max, maximal oxygen uptake HFSS, Heart Failure Survival Score; 
ICD, implantable cardioverter defibrillator; LV, left ventricular; NT-proBNP, N-terminal 
pro-B-type natriuretic peptide; NYHA class IV, New York Heart Association; SHFM, 
Seattle Heart Failure Model.  
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considered (Box 2). Alternatively, abnormally low O2 peak may suggest a cardiovascular 
limitation due to reduction in cardiac output, arterial O2 content, muscle oxygen extraction, 
and/or ineffective vascular shunt.  Although O2peak quantifies cardiorespiratory fitness 
(CRF), it does not indicate the cause of an exercise limitation and it is necessary to conduct 
further assessment to determine any underlying pathophysiology. 
Cardiopulmonary exercise tests are often conducted in patients with a known clinical 
diagnosis. In these circumstances a lower O2 peak may be expected, therefore it may be 
useful to compare test results with “normative” values for a specific patient group. Table 1 
illustrates how CPET can distinguish between different pathologies by comparing a healthy 
individual with a CHF and chronic obstructive pulmonary disease patient.  Whilst O2 peak is 
considered by many to be the primary CPET-derived outcome variable, its reproducibility 
and prognostic power are affected by a number of factors including patient effort, test 
protocol design, familiarity, and disease severity. Alternative markers of aerobic capacity 
such as the ventilatory anaerobic threshold (VAT) can be used to improve prognostic power 
and assist in the quantification of CRF.  
 
 
 
 
 
 
 
 
 
 
 
Box 2: Maximal Effort Criteria  
• Failure of HR to increase with further increases in exercise intensity (achieving 
>85% of age-predicted maximal HR is a well-recognised indicator of patient effort) 
• A plateau in O2 (or failure to increase by 150 mL.min-1) with an increased 
workload 
• A respiratory exchange ratio (RER = CO2/ O2) at peak exercise > 1.10  
• A rating of perceived exertion (RPE) > 17 on the 6-20 Borg scale or >9 on the 0-10 
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Table 1. Interpretation of CPET data for a healthy male (Figure 1); a patient with chronic 
heart failure (Figure 2); a patient with emphysema and mild-moderate obstructive lung 
disease (Figure 3).   
 
 
 
 
PLOT  HEALTHY (FIG 1) CHF (FIG 2) COPD (FIG 3) 
PLOT 1  
Peak VO2 within normal 
predicted range  
(102% of predicted) 
 
ΔVO2/ΔWR slope normal 
(9.8ml/min/W) 
 
Peak VO2 low 
(52% of predicted) 
 
 
ΔVO2/ΔWR slope low 
(5.7ml/min/W) 
 
Peak VO2 low  
(63% of predicted) 
 
 
ΔVO2/ΔWR slope low  
(7.3 ml/min/W) 
PLOT 2  
Normal O2/HR  
(97% of predicted) 
 
Normal peak HR  
(107% of predicted) 
 
 
O2/HR flattens after 2 
minutes of exercise 
 
Peak HR low 
(56% of predicted) 
 
 
Normal O2/HR 
(84% of predicted) 
 
HRR High 
PLOT 3  
VAT normal  
(49% of predicted VO2peak) 
 
 
VAT low 
(38% of predicted VO2peak) 
 
VAT low 
(41% of predicted VO2peak) 
PLOT 4  
Normal ventilatory equivalents 
 
VE/VCO2 at VAT high (44) 
Suggesting elevated VD/VT 
 
 
Ventilatory equivalents 
high (increased VD) 
 
PLOT 5 N/A N/A N/A 
PLOT 6 Normal (<34) Elevated  Elevated 
PLOT 7  
Normal partial pressures 
 
 
Normal SPO2 
 
 
SPO2 Low at peak  
(88%) 
 
PLOT 8  
Normal RER 
 
Normal RER 
 
 
Normal RER 
PLOT 9  
Normal BR (93) 
 
 
Normal BR (39) 
 
Low BR (2) 
CPET, Cardiopulmonary exercise test; CHF, Chronic heart failure; VO2, Oxygen uptake; ∆VO2, Delta 
oxygen uptake; ∆WR, Delta work rate; COPD, Chronic obstructive pulmonary disease; HR, Heart rate; 
HRR, Heart rate reserve; VAT, Ventilatory anaerobic threshold; VE, Minute ventilation; VD, Ventilatory 
dead space; VT, Ventilatory tidal volume; SPO2, Arterial oxygen saturation; RER, Respiratory exchange 
ratio; BR, Breathing reserve 
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Ventilatory Anaerobic Threshold (VAT) 
During CPET, O2 and expired carbon dioxide ( CO2) increase linearly until the point 
where oxidative metabolism can no longer sustain the required workload. Anaerobic 
glycolysis is increasingly required for energy synthesis to maintain higher work rates leading 
to increased blood lactate accumulation. Bicarbonate buffering of associated H+ ions results 
in increased CO2 production that is ventilated to maintain pH balance. This causes a 
breakpoint in the linear relationship between O2 and O2 as shown in plot 3 the 9-
panel plot. This point marks the VAT (also known as VT1).   
The V-slope method is perhaps the most widely used technique for VAT determination 
(Beaver et al., 1986, Wasserman et al., 2011) and is achieved by plotting O2 as a function 
of O2. A trend line is drawn through the plots from the initiation of exercise to the point at 
which the linear relationship between O2 and O2 is lost (Slope slightly less than 1). A 
second trend line can then be drawn from the end of the test through to the deflection 
point. The point at which these two lines bisect indicates the VAT; a value in ml∙kg -1∙min-1 
should be reported which can then be calculated as a percentage of O2 peak.  
The ventilatory anaerobic threshold is considered a reliable marker of aerobic capacity since 
a low VAT indicates decreased O2 transport chain efficiency. Patients with superior CRF will 
have a VAT closer to their VO2peak, however for most patients VAT will lie between 40-60% 
of their peak aerobic capacity.  
A VAT <40% of peak O2 (or predicted O2 max) is indicative of disease pathology or 
significant physical deconditioning (Mezzani et al., 2009). A VAT <11 ml∙kg -1∙min-1 is 
commonly used to identify patients at higher peri-operative risk and is associated with a 5.3 
fold increase in mortality (Gitt et al., 2002). However, many CHF patients have 
heterogeneous muscle fibre types, abnormal metabolism and compromised exercise 
haemodynamics. These abnormalities preclude the detection of VAT with non-detection 
indicative of poor prognosis (Agostoni et al., 2013). 
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With increasing exercise intensity above the VAT, intracellular bicarbonate is no longer able 
to adequately offset metabolic acidosis. At this point an increase in VE in excess of VCO2 can 
be observed and marks the ventilatory compensation point (also referred to as VT2).  
 
 
 
Ventilatory Compensation Point  
 
The ventilatory compensation point (VCP) is a marker of the upper limit of sustainable 
aerobic exercise effort and therefore like VAT and O2 peak, is an important parameter 
describing O2 transport and utilisation. It is usually attained at approximately 70–80% 
VO2peak and 80–90% HR peak (Mezzani et al., 2013). The VCP is well-correlated to 'critical 
power' (Dekerle et al., 2003) representing the highest power sustainable in conditions of 
both VO2 and lactate steady state (i.e. at the limit between high and very-high exercise 
intensity domains). The VCP is identifiable in plot 6 of the 9-panel plot as an inflection in VE 
vs CO2 or inflection in VE/ CO2 (plot 4) with a concurrently occurring deflection point in 
end-tidal CO2 (PETCO2; plot 7). It is important to note that a VCP may not be identifiable in 
patients who have failed to achieve a near-maximal effort during CPET. 
 
VE/VCO2 slope  
The slope of the relationship between VE and CO2 (VE/ CO2 slope) during incremental 
exercise describes ventilatory efficiency and quantifies the ventilatory rate required to 
eliminate 1 litre of CO2 (plot 6 of the 9 panel plot). If an inappropriately high ventilatory 
response, caused by hyperactive peripheral chemoreceptors or increased VD/VT is present, 
PaCO2 will drop and the VE/ CO2 slope will steepen. Muscle ergoflex activation is also a 
proposed mechanism of increased VE/ CO2 slope in patients with CHF. Mathematically, the 
VE/ CO2 slope is determined by 3 factors: the amount of CO2 produced; the physiological 
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dead space/tidal volume ratio (VD/VT); and PaCO2. The relationship can be explained by the 
equation:  
VE = 863 x CO2 /PaCO2 (1-VD/VT) 
Where, 863 is a constant (corrects for different environmental conditions, and assumes core 
temperature of 37 °C), VD/VT is the physiological dead space/tidal volume ratio, and 
PaCO2 is the arterial CO2 partial pressure. A VE/ CO2 slope elevation  is a phenomenon 
frequently observed in CHF patients (Sullivan et al., 1988) and discriminating whether this 
anomaly is a result of a respiratory or circulatory aetiology can be challenging. Clinical 
evaluation of past medical history and presenting diagnosis may help distinguish the likely 
cause. 
A number of treatments have been shown to effectively lower VE/ CO2 slope including 
exercise training (Guazzi et al., 2004), angiotensin converting enzyme (ACE) inhibitors 
(Guazzi et al., 1999), cardiac resynchronisation therapy (Malfatto et al., 2005) and heart 
transplantation (Carter et al., 2006). Serial CPET may be advantageous in assessing the 
efficacy of such therapeutic interventions. Most contemporary metabolic carts provide 
automated analysis of VE/ CO2 slope however the slope can be calculated by linear 
regression when plotting VE as a function of CO2. The mathematical method used to 
calculate this variable may make it more reproducible (Bensimhon et al., 2008) than O2peak 
although adequate reproducibility data remains elusive.  Table 1 illustrates the differences 
in VE/ CO2 slope observed in a healthy male, a patient with CHF and a patient with chronic 
obstructive pulmonary disease (COPD). A VE/ CO2 slope >34 is commonly accepted as 
indicating poorer prognosis (Gitt et al., 2002, Arena et al., 2005, Ingle, 2007), although it is 
possible to further risk stratify patients according to a ventilatory classification system 
proposed by Arena et al (2007a). VE/ CO2 slope may also have a predictive role in the risk 
assessment of patients with coronary heart disease [CHD] (Van de Veire et al., 2006). 
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Figure 1. Adapted with permission from Lippincott Williams & Wilkins/Wolters Kluwer 
Health: Principles of Exercise Testing and Interpretation: Including Pathophysiology and 
Clinical Applications, Karlman Wasserman, James Hansen, Kathy Sietsema, Darryl Y. Sue, 
William W. Stringer, Xing-Guo  Sun, Brian J. Whipp ; Figure 10.1.1, Normal Male, 2011 
 
 
 
 
 
 
 
 
 
VO2, Oxygen uptake; VCO2, Expired carbon dioxide; WR, Work rate; HR, Heart rate; VE, Minute 
ventilation; SBP, Systolic blood pressure; VT, Ventilatory tidal volume; VC, Vital capacity; IC, 
Inspiratory capacity; MVV, Maximum voluntary ventilation; PETCO2, Partial pressure of end 
tidal carbon dioxide; PETCO2, Partial pressure of end tidal oxygen; PaO2, Partial pressure of 
arterial oxygen; PaCO2, Partial pressure of arterial carbon dioxide; R, Respiratory exchange 
ratio 
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Figure 2. Adapted with permission from Lippincott Williams & Wilkins/Wolters Kluwer 
Health: Principles of Exercise Testing and Interpretation: Including Pathophysiology and 
Clinical Applications, Karlman Wasserman, James Hansen, Kathy Sietsema, Darryl Y. Sue, 
William W. Stringer, Xing-Guo Sun, Brian J. Whipp; Figure 10.15.1, Chronic Heart Failure: 
Cardiomyopathy with Intraventricular Conduction Delay, 2011 
 
 
 
 
VO2, Oxygen uptake; VCO2, Expired carbon dioxide; WR, Work rate; HR, Heart rate; VE, Minute 
ventilation; SBP, Systolic blood pressure; VT, Ventilatory tidal volume; VC, Vital capacity; IC, 
Inspiratory capacity; MVV, Maximum voluntary ventilation; PETCO2, Partial pressure of end 
tidal carbon dioxide; PETCO2, Partial pressure of end tidal oxygen; PaO2, Partial pressure of 
arterial oxygen; PaCO2, Partial pressure of arterial carbon dioxide; R, Respiratory exchange 
ratio 
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Figure 3. Adapted with permission from Lippincott Williams & Wilkins/Wolters Kluwer 
Health: Principles of Exercise Testing and Interpretation: Including Pathophysiology and 
Clinical Applications, Karlman Wasserman, James Hansen, Kathy Sietsema, Darryl Y. Sue, 
William W. Stringer, Xing-Guo Sun, Brian J. Whipp; Figure 10.46.1, Emphysema with Mild 
Airway Obstruction, 2011 
 
 
 
 
VO2, Oxygen uptake; VCO2, Expired carbon dioxide; WR, Work rate; HR, Heart rate; VE, Minute 
ventilation; SBP, Systolic blood pressure; VT, Ventilatory tidal volume; VC, Vital capacity; IC, 
Inspiratory capacity; MVV, Maximum voluntary ventilation; PETCO2, Partial pressure of end 
tidal carbon dioxide; PETCO2, Partial pressure of end tidal oxygen; PaO2, Partial pressure of 
arterial oxygen; PaCO2, Partial pressure of arterial carbon dioxide; R, Respiratory exchange 
ratio 
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Measurement of circulatory function during CPET  
Oxygen pulse, heart rate, and VO2 versus work rate 
Exercise-induced myocardial ischaemia diagnosed through electrocardiographic (ECG) 
changes has poor sensitivity and specificity (Belardinelli et al., 2003). Ischaemia-induced left 
ventricular (LV) dysfunction however, occurs earlier in the ‘ischaemic cascade’ and may be 
detectable before ECG changes or symptoms of angina due to its deleterious effect on Q. In 
normal (healthy) physiology (Figure 1), Q is increased via a synergistic rise in HR and stroke 
volume (SV).  However, ischaemia-induced LV dysfunction during exercise can lead to abrupt 
reductions in SV and a concurrent attenuation of Q and VO2 response during CPET.   
Stroke volume can be estimated during CPET through the calculation of an exercise ‘oxygen 
pulse’ (O2/HR; dividing O2 by HR (units = ml O2 per beat)) in a modification of the Fick 
equation (Whipp et al., 1996). Oxygen pulse normally rises progressively throughout 
exercise, however a shallow rise in O2/HR, early plateau or inflection (figure 2, plot 2) 
suggests decreasing SV with  Q  being partially sustained through HR compensation at the 
onset of  myocardial ischaemia (Chaudhry et al., 2009).  
Early identification of an ischaemic threshold may also be observed with greater effect by 
combining O2/HR with the O2 versus work rate slope (Δ O2/ΔWR slope). In healthy 
individuals, a linear Δ O2/ΔWR slope of 10ml/min/watt is maintained until peak (Figure 1; 
plot 1), where at the upper limits of exercise, an inflection may occur, reflecting normal 
physiological limitation and O2 plateau. A uniform flattening of this relationship 
throughout CPET suggests a general reduction in cardiovascular efficiency (figure 2, plot 1) 
and may be attributed to conditions such as CHF. Cardiopulmonary exercise testing has 
good sensitivity and specificity in detecting exercise-induced myocardial ischaemia (87% and 
74% respectively). Belardinelli and colleagues (2003) established the criteria of Δ O2/ΔWR 
slope inflection and concurrent O2/HR inflection duration for the positive identification of 
exercise induced myocardial ischemia as compared to myocardial scintigraphy (area under 
the curve: 0.83). A value of 3.9ml/min/watt was selected as the strongest independent 
predictor of myocardial ischaemia using a hierarchical model.   
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The absence of Δ O2/ΔWR slope and O2/HR inflection can be considered negative criteria 
for myocardial ischaemia. It should be noted however that the application of this technique 
may be best suited to ramp protocols or protocols with small work increments for the 
reasons previously explained.  
 
Measurements of ventilatory function during CPET 
Oxygen uptake efficiency slope and VEqCO2 nadir  
Often during clinical exercise testing, true maximal criteria are not met and we therefore 
use the term O2peak. However, O2 peak can underestimate the true cardiorespiratory 
reserve and other key variables such as VE/ CO2 slope lose predictive power when exercise 
is not conducted beyond VAT (Ingle et al., 2007, Arena et al., 2007b). Results obtained from 
CPET that fail to elicit satisfactory patient effort may require an alternative assessment 
technique.  
The oxygen uptake efficiency slope (OUES) is calculated by plotting  O2  against the 
logarithmically transformed VE (Baba et al., 1996). The exponent of the linear relationship 
provides an index of oxygen uptake with respect to VE and reflects both the efficiency of 
oxygen delivery to the muscle and mitochondrial oxygen utilisation. OUES is only minimally 
altered when comparing submaximal to maximal test data (Hollenberg and Tager, 2000) 
with results differing by as little as 1% (Davies et al., 2006) and thus allowing an accurate 
index of CRF to be calculated. Furthermore the reproducibility of OUES has been shown to 
be superior to that of the VAT and O2peak (Van Laethem et al., 2009). An OUES of <1.4 is 
indicative of poor survival (hazard ratio: 4.3, 95% confidence interval: 2.4 to 7.9 p <0.001) 
regardless of whether VAT is reached (Arena et al., 2007b). 
 
The VEqCO2 nadir is the lowest point in the VE and CO2 relationship when plotted over the 
course of a CPET and normally occurs around the VAT in most patients (plot 4). Recent work 
from our laboratory (Ingle et al., 2011) has shown that this variable calculated from 
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submaximal data has greater prognostic value than other variables collected from maximal 
CPET. Therefore, in patient cohorts where a maximal CPET cannot be conducted (e.g. low 
functional capacity groups), the OUES and VEqCO2 nadir should be calculated to enhance 
risk stratification. 
Exercise oscillatory ventilation 
Exercise oscillatory ventilation (EOV) sometimes referred to as exercise periodic breathing 
(EPB) is characterised by a sino-soidal pattern of VE during incremental exercise to volitional 
exhaustion. It occurs in up to one third of patients with CHF and is associated with very poor 
outcome (Ingle et al., 2009). Whilst the genesis of EOV is unclear, two hypotheses have been 
postulated; the ventilatory hypothesis which is associated with abnormal chemoreceptor 
feedback, and the haemodynamic hypothesis which is concerned with fluctuations in 
cardiac output during incremental exercise.  
 
CPET-derived prognostic scoring systems 
With the advent of more powerful statistical analysis packages, there has been a move in 
recent years towards developing composite prognostic scoring systems and moving away 
from the traditional binary approach to risk stratification. The traditional approach focuses 
on the top performing variable(s) while discounting the additive or cumulative effect of a 
combination of different predictor variables. Composite risk scores, which combine the level 
of risk across a number of variables, have become more commonplace. The advantage of 
such an approach is that it allows the quantification of risk across the spectrum of abnormal 
responses. Increasingly, these models are beginning to utilise more data derived from CPET. 
For example, the Hull CPET risk score was recently developed by our laboratory. We found 
that individual predictors of mortality ranged from 0.60 to 0.71 (Harrell’s C statistic), but the 
optimal combination of EOV + VE/ CO2 slope + OUES + VEqCO2 nadir reached 0.75 in 
patients with mild-to-moderate CHF. The Hull CPET risk score had a significantly higher area 
under the curve (0.78) when compared to the Heart Failure Survival Score (AUC=0.70; 
P<0.001) (Ingle et al., 2014). Our findings indicate that data derived solely from CPET out-
performs traditional prognostic risk markers which are collected from a range of different 
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investigations. CPET appears to be a time efficient and cost effective modality for stratifying 
risk in patients with CHF.  
 
Patient case study 
Table 4 summarises the results of a CPET performed by a patient who attended our exercise 
laboratory for risk stratification and CRF assessment. The patient was a 62 year-old male 
(body mass index of 32kg∙m-2) in normal sinus rhythm with an unremarkable ECG. The 
patient complained of dyspnoea on light exertion and had recently been diagnosed with 
coronary heart disease and undergone elective percutaneous coronary intervention. 
Incremental CPET on a treadmill was performed and breath-by-breath cardiorespiratory 
data collected (averaged over 15 seconds). A maximal effort was confirmed as the patient 
met two of the criteria in box 2.  
The patient’s failure to achieve at least 75% of his predicted O2max (Wasserman et al., 
2011) was consistent with reduced CRF (Guazzi et al., 2012). Using standard exercise 
tolerance test criteria, his 12-minute test duration would have been considered ‘normal’.  
The reduction in CRF may have been due to severe deconditioning, however this was 
excluded as his VAT was within the normal range (>40% actual/predicted O2peak). Data 
were therefore suggestive of respiratory or cardiac limitation. Pre-test spirometry values 
from 3 reproducible attempts were within normal range and peak exercise breathing 
reserve (VEmax/estimated maximal voluntary ventilation) was also >20% suggesting 
adequate ventilation for the exercise intensity (Balady et al., 2010). The probability that 
respiratory disease was underlying exercise limitation was therefore deemed unlikely.  
The rise in O2/HR was blunted coinciding with a significantly steepened VO2/HR relationship 
suggesting SV limitation.  This pattern of LV dysfunction during exercise is consistent with 
myocardial ischaemia.  Both the OUES and VAT were pseudo-normal, but were suggestive of 
a reduction in O2 transport/utilisation. The VE/ CO2 slope however, was significantly 
elevated (>34) indicating inefficient ventilation and importantly, poor prognosis (30% 
likelihood of suffering a cardiac event within three years (Arena et al., 2007b). The most 
likely cause of the VE/ CO2 slope elevation was circulatory limitation, given the attenuation 
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of O2/HR and compensatory response of HR in relation to O2 needed to sustain Q.  The 
absence of any overt respiratory abnormality during spirometry; normal breathing reserve 
at peak exercise; history of PCI; and moderately reduced ejection fraction at rest support 
the conclusion that the patient’s exercise limitation was due to an underlying circulatory 
limitation.  
 
Conclusion 
The intention of this guide is to provide a concise, uncomplicated evidence based summary 
of CPET and present an approach to data interpretation for clinical decision-making. For this 
reason, detailed description of patient preparation procedures and technical aspects of 
equipment calibration/test conduction is beyond the scope of this guide. We recommend 
that readers review other key publications providing guidance for CPET (Balady et al., 2010, 
American Thoracic Society/American College of Chest Physicians, 2003). 
CPET is a safe, non-invasive assessment of cardiorespiratory function. It allows the 
determination of key prognostic variables and can distinguish pathophysiology not apparent 
at rest. It is able to discriminate cardiovascular, ventilatory and peripheral limitations during 
exercise by monitoring disturbances in key variable responses ( O2, VE, CO2 and HR). 
CPET offers additional interpretive power over conventional stress testing and thus can lead 
to improved clinical decision-making and risk stratification in patients with cardiometabolic 
and respiratory disease. 
 
5 KEY POINTS  
• Multiple factors (circulatory, ventilatory and metabolic) contribute to exercise 
intolerance across a wide spectrum of patients with cardiovascular disease. 
Establishing the aetiology and prognostic importance of exercise intolerance is a 
significant challenge for clinicians.  
 
• Cardiopulmonary exercise testing allows the determination of a number of powerful 
prognostic markers widely accepted in clinical practice 
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• Protocols that involve small to modest work rate increments per stage are preferred 
since they better preserve the relationship between oxygen uptake and work rate.  
 
• Multiple factors can affect exercise intolerance and a methodical approach to 
eliminating specific possible causes should be adopted. 
 
• Cardiopulmonary exercise testing offers a more comprehensive assessment of 
cardiorespiratory function than exercise tolerance tests and has been shown to have 
good sensitivity and specificity in the detection of exercise-induced myocardial 
ischaemia.  
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Table 4: A cardiopulmonary exercise test report  showing key variables for our patient case study  
 Patient Information 
Gender: Male Age: 61 
Height: 174.7cm Weight: 97Kg BMI: 31.67kg/m2 Waist-Hip Ratio: 1.06 
Blood Pressure: 100/78mmHg Pulse: 61bpm – Sinus Rhythm  
Past Medical History: PCI, Obesity, Gout Smoker: Yes- 20 per day 
Current Medications: Aspirin, Clopidogrel, 
Bisoprolol, Simvastatin, GTN Spray 
Reported Symptoms: Shortness of breath on 
exertion 
 
Spirometry Results 
PEF 7.6  ‡        
FVC 4.39 ‡ 
FEV1 3.4 ‡ 
FEV1/FVC Ratio 0.77 ‡ 
eMVV 136  
Breathing Reserve  44 ‡ 
 
CPET Results 
Test Duration Minutes: 12 ‡ Seconds: 1 
Criteria for Maximum Testing HR ≥ 85% predicted HR max (age & β-Blocker 
adjusted) ‡ 
Test Termination Criteria  Leg fatigue & inability to maintain required work 
rate  
VO2peak  20.6ml/Kg-1 (79.8% predicted maximum) ● 
Peak HR 130bpm (83% of predicted maximum) ◊ 
VAT 13.5ml/Kg-1 (66% VO2peak, 52% Predicted VO2peak ) 
OUES 1.9 ◊ 
VE/VCO2 Slope 42.19  ● 
O2/HR Blunted rise at 1minute 57 seconds ● 
VO2/HR Relationship Elevated at 4 minutes and 28 seconds  ● 
ST Segment Depression 1.8mm  ◊ 
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‡ = Within normal range; ◊ = Pseudo normal; ● = Abnormal 
BMI = Body mass index; PCI = Percutaneous coronary intervention; GTN, Glyceryl triniatrate; PEF = 
Peak expiratory flow; FVC = Forced vital capacity; FEV1 = Forced expiratory volume in 1 second; 
eMVV = estimated maximal voluntary ventilation; HR = Heart rate; VAT = Ventilatory anaerobic 
threshold; OUES = Oxygen uptake efficiency slope; VE = Minute ventilation; VCO2, expired carbon 
dioxide; VO2peak = peak oxygen uptake 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chest Pain Nil ‡ 
Breathing Reserve at Peak Exercise 22% ‡ 
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